Showing 116 of 116on this page. Filters & sort apply to loaded results; URL updates for sharing.116 of 116 on this page
AZD5305 inhibits and traps selectively PARP1 in cells. A, Left ...
AZD5305 | PARP | TargetMol
AstraZeneca's second-generation PARP inhibitor AZD5305 is applied for ...
AZD5305 / AstraZeneca
新一代 PARP 抑制剂！阿斯利康 AZD5305 国内启动临床_Insight_奥拉帕利_数据库
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression ...
(PDF) The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma ...
Effect of AZD5305 on PARP2 retention on DNA. (A) The crystal structure ...
Azd5305 – Application in Therapy and Current Clinical Research
Medchemexpress LLC HY-132167 5mg , AZD5305 CAS:2589531-76-8 Purity:>98% ...
AZD5305 + Darolutamide for Prostate Cancer Clinical Trial 2024 | Power
Study of AZD5305 Alone and with Other Cancer Drugs for Patients with ...
Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 ...
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients ...
Next-Generation PARP Inhibitor AZD5305 Shows Promising Safety Profile ...
AZD5305 More Tolerable than 1st-Generation PARP Inhibitors | GU ...
AZD5305 for Prostate Cancer Clinical Trial 2024 | Power
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other ...
PK/PD/efficacy relationship of AZD5305 in a BRCA1m TNBC xenograft tumor ...
AZD5305 (Saruparib; AZD-5305) | CAS 2589531-76-8 | AbMole BioScience ...
AZD5305 selectively targets cancer cells with HRR-deficiency, inducing ...
Study on the Safety and Effects of AZD5305 with Hormonal Agents for ...
AZD5305 reduces PARP2 mobility at cellular sites of DNA damage. (A ...
Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with ...
Antitumor efficacy of AZD5305 in combination with carboplatin in vivo ...
Saruparib (AZD5305) | PARP inhibitor | Mechanism | Concentration
Saruparib (AZD5305) | PARP Inhibitor | MedChemExpress
2022 AACR | 小分子领域：合成致死细化&PARP-1深度开发！__财经头条__新浪财经
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and ...
AACR 2022: PETRA: First in class, first in human trial of the next ...
How does AstraZeneca's PARP inhibitor differentiate?
恒瑞PARP1抑制剂出海带来的思考|抑制剂|首付款|实体瘤|恒瑞|专利|肿瘤|临床|-健康界
Preclinical Characterization of AZD5305, A Next-Generation, Highly ...
口服PARP1抑制剂AZD5305(Saruparib)治疗乳腺癌、胰腺癌、卵巢癌等,约50%的晚期肿瘤缩小_全球肿瘤医生网
Abstract CT007: PETRA: First in class, first in human trial of the next ...
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl ...
RCSB PDB - 9ETQ: Crystal structure of PARP1 catalytic domain bound to ...
Medchem story behind the discovery of PARP-1 selective inhibitor ...
AZD-5305 | 2589531-76-8
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody ...
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA ...
saruparib (AZD5305) / AstraZeneca
PARP赛道新势力：氟唑帕利、帕米帕利、AZD5305 2020年12月14， 恒瑞 开发的PARP抑制剂氟唑帕利正式获得NMPA批准上市 ...
Abstract ND05: Discovery and first structural disclosure of AZD5305: A ...
(PDF) Preclinical Characterization of AZD5305, A Next-Generation ...
PARP1 Olaparib Competitive Inhibitor Assay Kit PARP1 82293
AZD8205（B7-H4 ADC）联合AZD5305的临床前研究 - 平头哥
阿斯利康第二代PARP抑制劑AZD5305申報臨床 - 每日頭條
阿斯利康第二代PARP1抑制剂AZD5305联合AZD9833治疗BRCA或PALB2突变的晚期乳腺癌患者 - 知乎
2022 AACR | 小分子领域：合成致死细化&PARP-1深度开发！__财经头条
A unified mechanism for PARP inhibitor-induced PARP1 chromatin ...
前列腺癌新药临床试验：PARP1抑制剂Saruparib（AZD5305）-印塔健康官网
PARP抑制剂：氟唑帕利、帕米帕利、AZD5305对比-觅健
Abstract B070: Antitumor effect of AZD5305, a selective PARP1 inhibitor ...
80551 | PARP1 Chemiluminescent Assay Kit Clinisciences
PARP1 Homogenous Assay Kit
阿斯利康的PARP抑制剂如何差异化？|阿斯利康|奥拉帕利|抑制剂|卵巢癌|适应症|-健康界
2022AACR | AZ首爆新一代PARPi人体临床试验数据，直击安全性痛点，对多癌种有效-世展网
阿斯利康的PARP抑制剂如何差异化？
FDA撤销适应症，PARP下一步该怎么走？
AZD5305|CAS 2589531-76-8|DC Chemicals
恒瑞PARP1抑制剂HRS-1167出海带来的思考
阿斯利康第二代PARP抑制剂AZD5305申报临床 7月6日，CDE官网显示， 阿斯利康 第二代PARP（高选择性PARP1）抑制剂 ...
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
